Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 11/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703649 | 1.00 | SIGMAR1 (0.50) | SIGMAR1TMEM97PARP1PKMPTGDR2 | |
| SCHEMBL3068759 | 0.91 | PARP1 (0.48) | SIGMAR1TMEM97PARP1PTGDR2 | |
| SCHEMBL20449099 | 0.89 | PARP1 (0.53) | SIGMAR1TMEM97PARP1 | |
| SCHEMBL3155289 | 0.89 | PARP1 (0.53) | SIGMAR1TMEM97PARP1 | |
| SCHEMBL2706487 | 0.88 | PARP1 (0.48) | SIGMAR1TMEM97PARP1PTGDR2 | |
| SCHEMBL20449106 | 0.88 | PARP1 (0.48) | SIGMAR1TMEM97PARP1PTGDR2 | |
| SCHEMBL2708064 | 0.87 | PARP1 (0.46) | SIGMAR1TMEM97PARP1PTGDR2 | |
| SCHEMBL2488624 | 0.85 | PARP1 (0.46) | SIGMAR1TMEM97PARP1PKMPTGDR2 | |
| SCHEMBL4859941 | 0.85 | PARP1 (0.46) | SIGMAR1TMEM97PARP1PKMPTGDR2 | |
| SCHEMBL30969901 | 0.81 | PARP1 (0.44) | SIGMAR1TMEM97PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032651-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| CN-101370776-A | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARM INC (US) | 2009-02-18 | — | — | CN | disclosed |
| EP-1957458-A2 | 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES | Elan Pharmaceuticals Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007064914-A2 | 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES | ELAN PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | SIGMAR1 3233/4885TMEM97 3415/4885PARP1 1723/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | SIGMAR1 3050/4885TMEM97 3985/4885PARP1 1695/4885 |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | SIGMAR1 590/4885TMEM97 1929/4885PARP1 2509/4885 |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | SIGMAR1 590/4885TMEM97 1929/4885PARP1 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.